Enzymatica publ AB - Asset Resilience Ratio
Enzymatica publ AB (ENZY) has an Asset Resilience Ratio of 22.17% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Enzymatica publ AB strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2024)
This chart shows how Enzymatica publ AB's Asset Resilience Ratio has changed over time. See ENZY net asset quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Enzymatica publ AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ENZY company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr33.08 Million | 22.17% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr33.08 Million | 22.17% |
Asset Resilience Insights
- Good Liquidity Position: Enzymatica publ AB maintains a healthy 22.17% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Enzymatica publ AB Industry Peers by Asset Resilience Ratio
Compare Enzymatica publ AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
SIMCERE PHARMAC. GRP LTD
F:S2P |
Drug Manufacturers - Specialty & Generic | 0.44% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
Annual Asset Resilience Ratio for Enzymatica publ AB (2020–2024)
The table below shows the annual Asset Resilience Ratio data for Enzymatica publ AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 38.53% | Skr75.21 Million ≈ $8.09 Million |
Skr195.22 Million ≈ $21.01 Million |
+31.88pp |
| 2023-12-31 | 6.64% | Skr8.37 Million ≈ $900.32K |
Skr125.91 Million ≈ $13.55 Million |
-22.42pp |
| 2022-12-31 | 29.06% | Skr50.69 Million ≈ $5.45 Million |
Skr174.41 Million ≈ $18.77 Million |
+8.93pp |
| 2021-12-31 | 20.13% | Skr31.62 Million ≈ $3.40 Million |
Skr157.04 Million ≈ $16.90 Million |
+5.31pp |
| 2020-12-31 | 14.82% | Skr24.02 Million ≈ $2.58 Million |
Skr162.03 Million ≈ $17.44 Million |
-- |
About Enzymatica publ AB
Enzymatica AB (publ), a life science company, develops and sells medical devices for infection-related diseases. The company's product includes ColdZyme, a mouth spray that protects against the upper respiratory viruses that can cause cold and flu symptoms. It also provides enzyme formulations for skin care. The company was incorporated in 2007 and is headquartered in Lund, Sweden.